Dr. Yukiko Asaeda, MD
With 15 years of experience in several different capacities with some of the world's largest biopharmaceutical companies, Dr. Asaeda understands what it means to analyze the business opportunities in healthcare and build a solid sustainable business from scratch. In her corporate career, Dr. Asaeda ascended to leadership positions at exceptionally "young" age in Medical Affairs, Clinical Development, and Safety in Japan. In these capacities, she has worked at the local, regional and global level. In addition, she is a licensed and practicing physician and sees patients regularly. In doing so, Dr. Asaeda has witnessed firsthand some of the gaps that exist in the provision of healthcare in Japan, which makes her all the more passionate about making a real difference in patients’ lives and their healthcare. Dr. Asaeda's areas of interest include rare diseases and oncology.
Dr Asaeda is adept at building trusted networks of local medical doctors, including Thought Leaders, and patient communities, including patient advocacy groups. Her team has more than 35 years of combined direct experiences in the pharmaceutical industry and brings a unique set of expertise to devise transformative programs to their clients.
Mr. Kazuyoshi Hatanaka
Mr. Hatanaka is a senior executive in pharmaceutical and healthcare sectors. Currently he actively engages with patient-centric initiatives in Japanese healthcare, in particular in the pharma industry via non-profit organization, Japan Partners for Patient Centric Care (JPPaC), which he founded in 2014. Through JPPaC, he is leading multiple initiatives that support an equal partnership between patients groups or advocacy and pharmaceutical industry. Previously he held numerous executive positions, including Corporate Officer at Astellas Pharma, Chairman and CEO of Yamanouchi Pharma US, UK and Europe (now merged to Astellas Pharma), Professor at Japan University of Economic, Graduate School of Pharmacy Management Research Center, Professor for the MBA program at Kagawa University, Statutory Auditor at TOHO Holdings Co.Ltd. (listed on Tokyo Stock Exchange 1) and Hatanaka Pharma Consulting, where he founded to advise pharmaceutical companies in Japan to go through transformational changes in the competitive Japanese market.
Dr. Michihiko Wada, MD, PhD
Dr. Wada is a Professor at Clinical and Translational Research Center at Keio University, where he has been building a country-wide infrastructure of registry of rare and intractable diseases in order to help advance associated drug development in Japan. He concurrently serves in a number of advisory roles, including with the Japan Agency for Medical Research and Development (AMED). He is a representative of Japan with the Chrysalis Project Task Force for International Rare Diseases Research Consortium (IRDiC) and is an advocate for helping patients with rare diseases. Previously, he held many executive and leadership positions in the pharmaceutical industry as well as in academia, including as Director of Personalized Medicine at Kanazawa Advanced Medical Center at Kanazawa University, VP of R&D at Alexion Pharmaceuticals Japan and Head of Oncology and Specialty Medicine, Clinical Development at Bayer Pharmaceuticals Japan. He graduated from the University of Kyoto with an M.D. and PhD and specialized training in the HepatoBiliary Pancreatic surgery.
We are a team of Medical Doctors, Pharmacists, Scientists, and Industry Experts in R&D, Medical Affairs, Regulatory Affairs, Market Access, Commercial and Business Development. Our diverse and unique experiences help deliver high-value outcomes for both businesses and patients.
Head Office in Tokyo and Offshore Office in several locations around the world, supporting back office functions.
Patientricity MedPartners K.K.
2F 4-26-28 Jingumae, Shibuya, Tokyo, Japan 150-0001
Establishment: Sept, 2019
Representative: Yukiko Asaeda, MD
Business: Strategic consulting and advisory services for biopharma & biotech entering to Japan: medical affairs, clinical development, pharmacovigilance, market access, regulatory affairs